130 related articles for article (PubMed ID: 25841697)
1. Targeted therapy for lung cancer: present and future.
Aggarwal C
Ann Palliat Med; 2014 Jul; 3(3):229-35. PubMed ID: 25841697
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
4. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.
Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T
Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Reungwetwattana T; Weroha SJ; Molina JR
Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
[TBL] [Abstract][Full Text] [Related]
6. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
D'Arcangelo M; Wynes MW; Hirsch FR
Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
[TBL] [Abstract][Full Text] [Related]
7. From platinum compounds to targeted therapies in advanced thoracic malignancies.
Jakopovic M; Thomas A; Lopez-Chavez A
Anticancer Res; 2014 Jan; 34(1):477-82. PubMed ID: 24403504
[TBL] [Abstract][Full Text] [Related]
8. Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy.
Morodomi Y; Takenoyama M; Inamasu E; Toyozawa R; Kojo M; Toyokawa G; Shiraishi Y; Takenaka T; Hirai F; Yamaguchi M; Taguchi K; Seto T; Sugio K; Ichinose Y
Anticancer Res; 2014 Jul; 34(7):3825-30. PubMed ID: 24982409
[TBL] [Abstract][Full Text] [Related]
9. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
10. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
Mano H
Cancer Sci; 2008 Dec; 99(12):2349-55. PubMed ID: 19032370
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
12. Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer.
Kobayashi M; Sakakibara T; Inoue A; Fukuhara T; Sasano H; Ichinose M; Nukiwa T
Respir Investig; 2014 Jan; 52(1):49-56. PubMed ID: 24388371
[TBL] [Abstract][Full Text] [Related]
13. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
14. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
15. Extending survival of stage IV non-small cell lung cancer.
Carnio S; Novello S; Mele T; Levra MG; Scagliotti GV
Semin Oncol; 2014 Feb; 41(1):69-92. PubMed ID: 24565582
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
[TBL] [Abstract][Full Text] [Related]
17. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
Vari S; Pilotto S; Maugeri-Saccà M; Ciuffreda L; Cesta Incani U; Falcone I; Del Curatolo A; Ceribelli A; Gelibter A; De Maria R; Tortora G; Cognetti F; Bria E; Milella M
Expert Opin Drug Discov; 2013 Nov; 8(11):1381-97. PubMed ID: 24088065
[TBL] [Abstract][Full Text] [Related]
18. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.
Moskalev EA; Frohnauer J; Merkelbach-Bruse S; Schildhaus HU; Dimmler A; Schubert T; Boltze C; König H; Fuchs F; Sirbu H; Rieker RJ; Agaimy A; Hartmann A; Haller F
Lung Cancer; 2014 Jun; 84(3):215-21. PubMed ID: 24674157
[TBL] [Abstract][Full Text] [Related]
19. Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy.
Koh PK; Faivre-Finn C; Blackhall FH; De Ruysscher D
Cancer Treat Rev; 2012 Oct; 38(6):626-40. PubMed ID: 22196919
[TBL] [Abstract][Full Text] [Related]
20. Emerging protein kinase inhibitors for non-small cell lung cancer.
Liu SV; Subramaniam D; Cyriac GC; Abdul-Khalek FJ; Giaccone G
Expert Opin Emerg Drugs; 2014 Mar; 19(1):51-65. PubMed ID: 24354593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]